Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

Article Abstract:

Low-molecular-weight heparin may offer safe and effective home treatment for patients with deep leg vein clots. Low-molecular-weight heparin requires neither intravenous administration nor close follow up because its anticlotting properties are more predictable. Researchers randomly assigned 500 patients with deep-vein clots and no other complications to either the traditional in-hospital intravenous treatment with standard heparin or twice daily injections of low-molecular-weight heparin administered by the patient or a family member at home. During the 3-month follow-up period, 5% of the home treatment group versus 7% of the hospital group experienced a recurrent, symptom-causing clot. Two patients in the hospital group had pulmonary embolisms and both died. Hemorrhages occurred in 2% of the home treatment group versus 1% of the hospital group, and minor bleeding occurred in six patients in each group. Two patients in the home treatment group died of hemorrhages. Hospital stay in the home treatment group averaged 1.1 days versus 6.5 days in the hospital treatment group.

Author: Gent, Michael, Anderson, David, Hirsh, Jack, Geerts, William, Kovacs, Michael, Levine, Mark, Brien, William, Turpie, Alexander G., Leclerc, Jacques, Powers, Peter J., Willan, Andrew, Haley, Susan, Demers, Christine, Weitz, Jeffrey, Ginsberg, Jeffrey, Kassis, Jeanine, Desjardins, Louis, Cusson, Jean, Cruickshank, Moira
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
Health aspects, Drug therapy, Thrombosis, Deep vein, Deep vein thrombosis, Heparin

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism

Article Abstract:

A model that categorizes people as having a low, moderate, or high risk of pulmonary embolism appears to be helpful when interpreting ventilation-perfusion lung scans. Pulmonary embolism occurs when a blood clot forms in the legs and travels to the lungs. Ventilation-perfusion lung scans are often used to diagnose pulmonary embolism. In a study of 1,239 patients who had a ventilation-perfusion lung scan, only 3% of those with a low risk actually had pulmonary embolism as determined by the lung scan compared to 28% with a moderate risk and 78% of those with a high risk.

Author: Gent, Michael, Ginsberg, Jeffrey S., Hirsh, Jack, Kearon, Clive, Anderson, David R., Turpie, Alexander G., Wells, Philip S., Barnes, David, Chamberlain, Michael, Weitz, Jeffrey, Bormanis, Janis, Bowie, Dennis
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1998
Diagnosis, Pulmonary embolism, Ventilation-perfusion ratio, Lung ventilation-perfusion scan

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Similar abstracts:
  • Abstracts: Evaluation of the cost-effectiveness of home monitoring of uterine contractions
  • Abstracts: Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. part 2
  • Abstracts: Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment
  • Abstracts: Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation
  • Abstracts: Interruption of professional and home activity after laparoscopic cholecystectomy among French and American patients
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.